Sixth Annual Wisconsin Review of the San Antonio Breast Cancer Symposium

Saturday, January 23, 2021
7:00 AM - 12:15 PM

This educational activity is jointly provided by AXIS Medical Education and Wisconsin Association of Hematology and Oncology (WAHO).

Target audience

This activity is intended for all members of the interprofessional cancer care team including physicians, nurses, nurse practitioners, pharmacists, physician assistants, managers, billers/coders, and social workers.       

Overview

This educational activity provides information on recently validated clinical tools and advances in genetic testing for the treatment of breast cancer. Participants will hear the latest updates in clinical research, science, and healthcare policies to optimize their delivery of high-quality, high-value care to patients with cancer. All members of the cancer care team who are interested in learning about current advances in breast cancer research; translational science that will impact the future of breast cancer care; and the effects of COVID-19 on patient outcomes are encouraged to participate.

Learning Objectives

At the end of this educational activity, participants should be able to:

  1. Discuss recent advancements in the treatment of HER2-positive, ER-positive, and triple-negative breast cancer. 
  2. Evaluate the use of genomic assays and biomarkers for managing patients with breast cancer. 
  3. Apply skills and strategies about localized therapies to the care of patients with breast cancer.
  4. Describe the impact of COVID-19 on outcomes in patients with breast cancer.

Agenda

7:00 - 7:55 AM 
Registration/Virtual Resource Center

7:55 - 8:00 AM  
Welcome and Introductions
Benjamin M. Parsons, DO
President, Wisconsin Association of Hematology and Oncology

Kari B. Wisinski, MD [Moderator]
University of Wisconsin Carbone Cancer Center

8:00 - 8:30 AM 
Advances in HER2 - Positive Breast Cancer
William J. Gradishar, MD, FACP, FASCO
Northwestern University Feinberg School of Medicine

8:30 - 9:15 AM  
Localized Therapies
Jessica M. Schuster, MD
University of Wisconsin School of Medicine and Public Health

Caitlin Patten, MD
Medical College of Wisconsin                    

9:15 - 9:45 AM  
ER-Positive Breast Cancer
Ruth M. O'Regan, MD
University of Wisconsin Carbone Cancer Center

9:45 - 10:15 AM 
Break/Virtual Resource Center                          

10:15 - 10:45 AM 
Triple Negative Breast Cancer
Yee Chung Cheng, MD
Froedtert & the Medical College of Wisconsin

10:45 - 11:15 AM 
Genomic Assays and Biomarkers in Breast Cancer
Elisavet Paplomata, MD
University of Wisconsin Carbone Cancer Center 

11:15 - 11:45 AM
COVID-19 and Breast Cancer Outcomes
Tracy R. Kelly, MD
Froedtert Hospital Cancer Center

11:45 AM - 12:15 PM
Closing Remarks/Acknowledgements
   

ACCREDITED CONTINUING EDUCATION

Accreditation Statement

Jointly Accredited Provider LogoIn support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Wisconsin Association of Hematology and Oncology (WAHO). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

IPCE Logo

This activity was planned by and for the healthcare team, and learners will receive 3.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 3.25 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity

AXIS Contact Information
For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

 

Name of Faculty or Presenter/Planner

Reported Financial Relationship

 

 

Yee Chung Cheng, MD

Nothing to Disclose

William J. Gradishar, MD, FACP, FASCO

Advisor/Consultant: AstraZeneca, Daiichi Sankyo, Roche/Genentech, MacroGenics, Seattle Genetics

Tracy R. Kelly, MD

Nothing to Disclose

Ruth O'Regan, MD

Advisor: Biotheranostics, Cyclacel, Genentech, Lilly, MacroGenics, Novartis, Pfizer, Puma, Seattle Genetics
Research Research Grants from and Contracted Research: Eisai, Novartis, Pfizer, Seattle Genetics

Elisavet Paplomata, MD

Advisory Board: Puma
Speaker's Bureau: OncLive
Received Research Grant from: Immunogen, Novartis

Caitlin Patten, MD

Nothing to Disclose

Jessica M. Schuster, MD

Nothing to Disclose

Kari B. Wisinski, MD

Advisory Board: AstraZeneca, Daiichi Sankyo, Genomic Health, Pfizer
Received Research Grant from: Pfizer

 

The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:

 

Name of Planner/Manager/Reviewer Reported Financial Relationship
   

LuAnne Bankert, CAE 

Nothing to Disclose

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to Disclose

Sailaja Kamaraju, MD, MS

Speakers Bureau: Pfizer
Received Income: Athenex Oncology
Contracted Research: Context Therapeutics

Dee Morgillo, MEd.,MT (ASCP) CHCP 

Nothing to Disclose

Benjamin M. Parsons, DO

Speakers Bureau: Amgen, AstraZeneca, Bristol Myers Squibb

Ronald Viggiani, MD

Nothing to Disclose

 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

  • Attend/participate in the educational activity and review all course materials.

  • Complete the CE Declaration form online by 11:59 PM ET within 14 days of the conclusion of each activity. Instructions will be provided during the activity.  

  • Upon successful completion of the online form, your statement of completion will be presented to you to print.


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
waho-wisconsin.com
Email Us